Literature DB >> 19513565

The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma.

Jun Yu1, Etmar Bulk, Ping Ji, Antje Hascher, Steffen Koschmieder, Wolfgang E Berdel, Carsten Müller-Tidow.   

Abstract

Decreased expression levels of EPHB6, a member of the receptor tyrosine kinases (RTKs), are associated with an increased risk of metastasis development in early stage non-small cell lung cancer (NSCLC). However, the signaling properties of the kinase-defective EPHB6 receptor are not well-understood. Here, we show that expression of EPHB6 in A549 lung adenocarcinoma cells led to phosphorylation of the MAP kinase ERK. Conversely, siRNA based knockdown of EPHB6 reversed ERK phosphorylation. Intriguingly, EPHB6-induced phosphorylation of ERK was uncoupled by activation of the Elk-1 transcriptional factor. These analyses suggest that kinase defective EPHB6 can lead to MAPK activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513565     DOI: 10.3892/ijo_00000326

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  EPH-EPHRIN in human gastrointestinal cancers.

Authors:  Haruhiko Sugimura; Jian-Dong Wang; Hiroki Mori; Masaru Tsuboi; Kiyoko Nagura; Hisaki Igarashi; Hong Tao; Ritsuko Nakamura; Hiroko Natsume; Tomoaki Kahyo; Kazuya Shinmura; Hiroyuki Konno; Yasushi Hamaya; Shigeru Kanaoka; Hideki Kataoka; Xiao-Jun Zhou
Journal:  World J Gastrointest Oncol       Date:  2010-12-15

Review 2.  Guidance molecules in lung cancer.

Authors:  Patrick Nasarre; Vincent Potiron; Harry Drabkin; Joëlle Roche
Journal:  Cell Adh Migr       Date:  2010-01-07       Impact factor: 3.405

3.  High expression of EphB6 protein in tongue squamous cell carcinoma is associated with a poor outcome.

Authors:  Yingchun Dong; Jicheng Pan; Yanhong Ni; Xiaofeng Huang; Xiao Chen; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma.

Authors:  Guiyuan Li; Shengming Yi; Fan Yang; Yongxin Zhou; Qiang Ji; Jianzhi Cai; Yunqing Mei
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

5.  Exploring Mouse Protein Function via Multiple Approaches.

Authors:  Guohua Huang; Chen Chu; Tao Huang; Xiangyin Kong; Yunhua Zhang; Ning Zhang; Yu-Dong Cai
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

6.  Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.

Authors:  James M Paul; Behzad Toosi; Frederick S Vizeacoumar; Kalpana Kalyanasundaram Bhanumathy; Yue Li; Courtney Gerger; Amr El Zawily; Tanya Freywald; Deborah H Anderson; Darrell Mousseau; Rani Kanthan; Zhaolei Zhang; Franco J Vizeacoumar; Andrew Freywald
Journal:  Oncotarget       Date:  2016-08-02

7.  EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Authors:  Behzad M Toosi; Amr El Zawily; Luke Truitt; Matthew Shannon; Odette Allonby; Mohan Babu; John DeCoteau; Darrell Mousseau; Mohsin Ali; Tanya Freywald; Amanda Gall; Frederick S Vizeacoumar; Morgan W Kirzinger; C Ronald Geyer; Deborah H Anderson; TaeHyung Kim; Alana L Welm; Peter Siegel; Franco J Vizeacoumar; Anthony Kusalik; Andrew Freywald
Journal:  Oncogene       Date:  2018-04-27       Impact factor: 9.867

8.  DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.

Authors:  Jia-En Wu; Yi-Ying Wu; Chia-Hao Tung; Yao-Tsung Tsai; Hsuan-Yu Chen; Yuh-Ling Chen; Tse-Ming Hong
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.